




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|---|
| (51) International Patent Classification ⁶ : A61K 39/39 // (A61K 39/39, 47:40, 47:34) | | A1 | (11) International Publication Number: WO 99/10008 |
| | | | (43) International Publication Date: 4 March 1999 (04.03.99) |
| (21) International Application Number: PCT/US98/17940 | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KB, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | |
| (22) International Filing Date: 28 August 1998 (28.08.98) | | | |
| (30) Priority Data: 60/057,255 29 August 1997 (29.08.97) US | | | |
| (71) Applicant: AQUILA BIOPHARMACEUTICALS, INC. [US/US]; 365 Plantation Street, Worcester, MA 01605-2376 (US). | | | |
| (72) Inventors: KENSIL, Charlotte; 15 Camp Street, Milford, MA 01757 (US). BELTZ, Gerald, A.; 4 Eustis Street, Lexington, MA 02173 (US). | | | |
| (74) Agents: SUPERKO, Colleen et al.; Hale and Dorr LLP, 60 State Street, Boston, MA 02109 (US). | | Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> | |

(54) Title: COMPOSITIONS COMPRISING THE ADJUVANT QS-21 AND POLYSORBATE OR CYCLODEXTRIN AS EXCIPIENT



(57) Abstract

Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

COMPOSITIONS COMPRISING THE ADJUVANT QS-21 AND POLYSORBATE OR CYCLODEXTRIN AS EXIPIENT

FIELD OF THE INVENTION

5 The present invention relates to the field of immune adjuvants and the use thereof as immune adjuvants in vaccines. The compositions of the present invention exhibit significantly improved properties relevant to the lytic effect, tolerance to QS-21 associated pain, and product stability of QS-21, and
10 maintain full adjuvant activity.

BACKGROUND OF THE INVENTION

15 Adjuvant saponins have been identified and purified from an aqueous extract of the bark of the South American tree, *Quillaja saponaria* Molina. Among the 22 peaks which were separable and displayed saponin activity, QS-21 was one of the more predominant purified saponins. This saponin has
20 been substantially purified by high pressure liquid chromatography (HPLC), low pressure liquid silica chromatography, and hydrophilic interactive chromatography (HILIC). QS-21 has been found to be useful as an immune adjuvant for enhancing immune responses in individuals at a much lower
25 concentration than the previously available heterogeneous saponin preparations without the toxic effects associated with crude saponin preparations.

 QS-21 is a membrane-lytic triterpene glycoside saponin. It forms micelles of approximately the same radius as bovine serum albumin (Kensil,
30 U.S. Patent No. 5,057,540) and has a critical micellar concentration of approximately 50 µg/ml in PBS (Soltysik, S., et al., 1995, Vaccine 13:1403-1410).

The potency of an adjuvant formulation containing an antigen plus QS-21 can be assessed in experiments that address the relationship of adjuvant dose to immunological function (dose-response experiments). A decrease in adjuvant potency is expected to increase the minimum dose (threshold dose) required for enhancement of immune response. A desirable composition is expected to maintain an equivalent or better potency than the formulation that is used as a reference. For QS-21, the reference formulation is a simple solution in phosphate-buffered saline (PBS) or saline.

The adjuvant activity of QS-21 is assessed in animal models such as mice. The primary responses measured are increases in antigen-specific antibody and antigen-specific cytotoxic T lymphocytes (CTL). The threshold dose of QS-21 that will enhance murine immune response (antibody or CTL) has been measured in simple buffer solution such as PBS. A dose of 2.5 µg has been shown to be the threshold dose for antibody (Kensil, C.R., et al., 1993, Vaccine Research 2:273-281) and for CTL (Newman, M.J., et al., 1992, J. Immunology 148:2357-2362) to the antigen ovalbumin (OVA) in C57BL/6 mice in PBS. Similar threshold doses were observed when aluminum hydroxide was included in the PBS formulation (Kensil, C.R., et al., 1993, Vaccine Research 2:273-281). However, it is expected that there may be differences in potency between different compositions of a given adjuvant.

Despite these beneficial qualities, QS-21 possesses some unwelcome qualities as well. For instance, QS-21 associates with phospholipid bilayers and causes a lytic effect on certain cell membranes (i.e., erythrocytes). QS-21 will absorb to the phospholipid bilayer of sheep erythrocytes and cause the red blood cells to release hemoglobin. This hemoglobin release, which is known as

hemolysis, occurs at a concentration of approximately 5-7 $\mu\text{g}/\text{ml}$ in a simple buffer such as saline or PBS (Kensil, C.R., et al., 1991, J. Immunology 146:431-437). At higher concentrations (above the critical micellar concentration of QS-21), total lysis of the red blood cell membrane occurs. The lytic effect of QS-21 is, therefore, an undesirable property for a composition.

In *in vivo* studies, hemolysis is not noted. However, after intramuscular injection of QS-21/saline solutions into New Zealand white rabbits, mild to moderate fibroblast damage or necrosis is noted in some animals when the injection site is analyzed histopathologically (Kensil, C.R., et al., 1995, In: Vaccine Design: The Subunit and Adjuvant Approach, Powell, M.F. and Newman, M.J., Eds., Plenum Press, NY). Further, creatine kinase, a marker for muscle damage is increased after injection with QS-21 in saline or PBS. This rise is believed to be due to the lytic effect of QS-21 on cell membranes.

Moreover, in clinical trials, some individuals have experienced an immediate, transient pain after injection with QS-21 in simple buffer solutions (saline or PBS). This pain, described by most individuals as a burning pain, may be a secondary reaction correlated with the lytic effect of the QS-21 adjuvant. Patient pain is likewise an objectionable property for a composition.

Product stability is another concern for QS-21 containing compositions. The shelf life of a vaccine product is typically defined by the extent of time to reach a defined and acceptable low level of degradation (such as, the time to 10% degradation, also known as t_{90}). Most commercial vaccine products have a shelf life of at least 18 to 24 months when stored in the refrigerator at 4°C. Adjuvants, which are essential components of vaccines, therefore must also have equally long shelf lives. However, the shelf life of a 50 $\mu\text{g}/\text{ml}$ solution of

QS-21 at pH 7.0 at 4°C is reached in about 3 months. The reason for the short shelf life is because the ester bond of QS-21 is increasingly labile at increasing pH and because monomers of QS-21, as opposed to micelles, are subject to
5 hydrolysis. The need to stabilize compositions of QS-21 adjuvant is significant.

SUMMARY OF THE INVENTION

A need exists for compositions of the saponin adjuvant QS-21 that may
10 be used to boost the antigenic immune response in a relatively low dose with low local reactions and side effects, but also features a reduced lytic effect, improved tolerance to QS-21, and an increased stability. Accordingly, the present invention provides novel compositions of QS-21 that have these
15 improved characteristics compared to a simple solution of QS-21 in a buffer such as saline or PBS. Surprisingly, the full adjuvant potency of QS-21 in the disclosed compositions is not compromised compared to a control formulation
20 of QS-21 in PBS.

DESCRIPTION OF THE FIGURES

Figure 1 depicts a graph showing the adjuvant potency of various
25 compositions. Figure 1A shows the effect of Polysorbate 40, Polysorbate 60, and Polysorbate 80 on the immune response of Balb/c mice to ovalbumin at different concentrations of QS-21. Figure 1B shows the effect of methyl- β -cyclodextrin on the immune response of Balb/c mice to ovalbumin at different
30 concentrations of QS-21.

Figure 2 depicts a graph showing the effect of Polysorbate 80 and hydroxypropyl- β -cyclodextrin on Type 14 IgG3 antibody response to a

T-independent polysaccharide antigen.

Figure 3 shows a bar graph of patients' tolerance to pain for various excipients in QS-21 adjuvant compositions from Trial 1. This figure shows how the pain scores are classified as no pain, mild pain, moderate pain, or severe pain, where 0=no pain, 1-3=mild pain, 4-7=moderate pain, and 8-10=severe pain.

Figure 4 shows the individual scores for the patients' tolerance to pain in Figure 3. This figure shows individual immediate pain scores after injection of a given formulation on a scale of 0-10, where 0 is no pain and 10 is maximum pain.

Figure 5 shows a bar graph of patients' tolerance to pain for various excipients in QS-21 adjuvant compositions from Trial 2. This figure shows how the pain scores are classified as no pain, mild pain, moderate pain, or severe pain, where 0=no pain, 1-3=mild pain, 4-7=moderate pain, and 8-10=severe pain.

Figure 6 shows the individual scores for the patients' tolerance to pain in Figure 5. This figure shows individual immediate pain scores after injection of a given formulation on a scale of 0-10, where 0 is no pain and 10 is maximum pain. Mean and median scores for each formulation are listed below each formulation.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The saponins of the present invention may be obtained from the tree *Quillaja saponaria* Molina.

The term "saponin" as used herein includes glycosidic triterpenoid

compounds which produce foam in aqueous solution, have hemolytic activity in most cases, and possess immune adjuvant activity. The invention encompasses the saponin per se, as well as biologically active fragments thereof.

The invention also concerns compositions, such as immunologic compositions, comprising one or more substantially pure saponin fractions, and methods of using these compositions as immune adjuvants.

More particularly, the compositions of the present invention may reduce the *in vitro* lytic effects of a saponin adjuvant containing formulation. Another preferred composition is one that may maintain the maximum adjuvant activity of a saponin. Yet another preferred composition may increase the stability of a saponin adjuvant containing composition from alkaline hydrolysis. Other compositions may preferably improve an individual's tolerance to saponin adjuvant associated pain from a formulation containing a saponin adjuvant.

As described in Kensil, et al., U.S. Patent No. 5,057,540, the contents of which are fully incorporated by reference herein, the adjuvant activity of such saponins may be determined by any of a number of methods known to those of ordinary skill in the art. The increase in antibody titer of antibody against specific antigen upon administration of an adjuvant may be used as a criteria for adjuvant activity. (Dalsgaard, *Acta Veterinaria Scandinavica*, 69:1 (1978); Bomford, *Int. Archs. Allergy Appl. Immun.* 77:409 (1985).) Briefly, one such test involves injecting CD-1 mice intradermally with an antigen (for instance, i.e., bovine serum albumin, BSA) mixed with varying amounts of the potential adjuvant. Sera was harvested from the mice two weeks later and tested by ELISA for anti-BSA antibody.

"QS-21" designates the mixture of isomeric components QS-21-V1 and QS-21-V2 which appear as a single peak on reverse phase HPLC on Vydac C4 (5 μ m particle size, 300Å pore, 4.6 mm ID x 25 cm) in 40 mM acetic acid in methanol/water (58/42, v/v). The component fractions are referred to specifically as QS-21-V1 and QS-21-V2 when describing experiments performed on the further purified components.

The term "substantially pure" means substantially free from compounds normally associated with the saponin in its natural state and exhibiting constant and reproducible chromatographic response, elution profiles, and biologic activity. The term "substantially pure" is not meant to exclude artificial or synthetic mixtures of the saponin with other compounds.

The substantially pure QS-7 saponin also referred to as QA-7 in U.S. Patent No. 5,057,540) is characterized as having immune adjuvant activity, containing about 35% carbohydrate (as assayed by anthrone) per dry weight, having a UV absorption maxima of 205-210 nm, a retention time of approximately 9-10 minutes on RP-HPLC on a Vydac C₄ column having a 5 μ m particle size, 300 Å pore, 4.6 mm ID x 25 cm L in a solvent of 40 mM acetic acid in methanol/water (58/42; v/v) at a flow rate of 1 ml/min, eluting with 52-53% methanol from a Vydac C₄ column having a 5 μ m particle size, 300 Å pore, 10 mm ID x 25 cm L in a solvent of 40 mM acetic acid with gradient elution from 50 to 80% methanol, having a critical micellar concentration of approximately 0.06% (w/v) in water and 0.07% (w/v) in phosphate buffered saline, causing no detectable hemolysis of sheep red blood cells at concentrations of 200 μ g/ml or less, and containing the monosaccharide residues terminal rhamnose, terminal xylose, terminal glucose, terminal

galactose, 3-xylose, 3,4-rhamnose, 2, 3-fucose, and 2,3-glucuronic acid, and apiose (linkage not determined).

The substantially pure QS-17 saponin (also referred to as QA-17 in U.S. Patent N. 5, 057, 540) is characterized as having immune adjuvant activity, containing about 29% carbohydrate (as assayed by anthrone) per dry weight, having a UV absorption maxima of 205-210 nm, a retention time of approximately 35 minutes on RP-HPLC on a Vydac C₄ column having a 5 µm particle size, 300 Å pore, 4.6 mm ID x 25 cm L in a solvent of 40 mM acetic acid in methanol/water (58/42; v/v) at a flow rate of 1 ml/min, eluting with 63-64% methanol from a Vydac C₄ column having a 5 µm particle size, 300 Å pore, 10 mM ID x 25 cm L in a solvent of 40 mM acetic acid with gradient elution from 50 to 80% methanol, having a critical micellar concentration of approximately 0.06% (w/v) in water and 0.03% (w/v) in phosphate buffered saline, causing hemolysis of sheep red blood cells at 25 µg/ml or greater, and containing the monosaccharide residues terminal rhamnose, terminal xylose, 2-fucose, is characterized as having immune adjuvant activity, containing about 35% carbohydrate (as assayed by anthrone) per dry weight, having a UV absorption maxima of 205-210 nm, a retention time of approximately 9-10 minutes on RP-HPLC on a Vydac C₄ column having a 5 µm particle size, 300 Å pore, 4.6 mm ID x 25 cm L in a solvent of 40 mM acetic acid in methanol/water (58/42; v/v) at a flow rate of 1 ml/min, eluting with 52-53% methanol from a Vydac C₄ column having a 5 µm particle size, 300 Å pore, 10 mM ID x 25 cm L in a solvent of 40 mM acetic acid with gradient elution from 50 to 80% methanol, having a critical micellar concentration of approximately 0.06% in water and 0.07% in phosphate buffered saline, causing no detectable

hemolysis of sheep red blood cells at concentrations of 200 µg/ml or less, and containing the monosaccharide residues terminal rhamnose, terminal xylose, 2-fucose, 3-xylose, 3,4-rhamnose, 2,3-glucuronic acid, terminal glucose, 2-arabinose, terminal galactose and apiose (linkage not determined).

The substantially pure QS-18 saponin (also referred to as QA-18 in U.S. Patent No. 5,057,540) is characterized as having immune adjuvant activity, containing about 25-26% carbohydrate (as assayed by anthrone) per dry weight, having a UV absorption maxima of 205-210 nm, a retention time of approximately 38 minutes on RP-HPLC on a Vydac C₄ column having a 5 µm particle size, 300 Å pore, 4.6 mm ID x 25 cm L in a solvent of 40 mM acetic acid in methanol/water (58/42; v/v) at a flow rate of 1 ml/min, eluting with 64-65% methanol from a Vydac C₄ column having a 5 µm particle size, 300 Å pore, 10 mM ID x 25 cm L in a solvent of 40 mM acetic acid with gradient elution from 50 to 80% methanol, having a critical micellar concentration of approximately 0.04% (w/v) in water and 0.02% (w/v) in phosphate buffered saline, causing hemolysis of sheep red blood cells at 25 µg/ml or greater, and containing the monosaccharide residues terminal arabinose, terminal apiose, terminal xylose, terminal glucose, terminal galactose, 2-fucose, 3-xylose, 3,4-rhamnose, and 2,3-glucuronic acid.

The substantially pure QS-21 saponin (also referred to as QA-21 in U.S. Patent No. 5,057,540) is characterized as having immune adjuvant activity, containing about 22% carbohydrate (as assayed by anthrone) per dry weight, having a UV absorption maxima of 205-210 nm, a retention time of approximately 51 minutes on RP-HPLC on a Vydac C₄ column having a 5 µm particle size, 300 Å pore, 4.6 mm ID x 25 cm L in a solvent of 40 mM acetic acid

in methanol/water (58/42; v/v) at a flow rate of 1 ml/min, eluting with 69-
70% methanol from a Vydac C₄ column having a 5 µm particle size, 300 Å pore,
10 mM ID x 25 cm L in a solvent of 40 mM acetic acid with gradient elution
5 from 50 to 80% methanol, having a critical micellar concentration of
approximately 0.03% (w/v) in water and 0.02% (w/v) in phosphate buffered
saline, causing hemolysis of sheep red blood cells at 25 µg/ml or greater. The
component fractions, substantially pure QS-21-V1 and QS-21-V2 saponins, have
10 the same molecular weight and identical spectrums by FAB-MS. They differ
only in that QS-21-V1 has a terminal apiose which is xylose in QS-21-V2 (which
therefore has two terminal xyloses and no apiose). The two components
additionally contain the monosaccharides terminal arabinose, terminal apiose,
15 terminal xylose, 4-rhamnose, terminal galactose, 2-fucose, 3-xylose, and 2,3-
glucuronic acid.

The invention may also encompass impure forms of saponin adjuvants.
20 For example, one preferred embodiment is the heterogenic saponin adjuvant
known as "Quil A." Commercial preparations of Quil A are available from
Superfos (Vedbaek, Denmark) and have been isolated from the bark of the
South American tree, *Quillaja saponaria* Molina. Quil A is characterized
25 chemically as carbohydrate moieties in glycosidic linkage to the triterpenoid
quillaic acid. Quil A possesses immune adjuvant activity and separates into 20
discrete peaks by RP-HPLC on Vydac C₄ column having a 5 µm particle size,
300 Å pore, 4.6 mM ID x 25 cm L in a solvent of 40 mM acetic acid in methanol
30 water (U.S. Patent No. 5,057,540).

The invention also relates to a composition which comprises a saponin
adjuvant of the present invention, an antigen, and an excipient. Preferably, the

adjuvant is QS-21. Preferably, the excipients may be nonionic surfactants, polyvinylpyrrolidone, human serum albumin, aluminum hydroxide, agents with anesthetic action, and various unmodified and derivatized cyclodextrins.

5 More preferably, the nonionic surfactants may include Polysorbate 20, Polysorbate 40, Polysorbate 60, and Polysorbate 80. The polyvinylpyrrolidone may preferably be Plasdone C15, a pharmaceutical grade of polyvinylpyrrolidone. The agent having anesthetic action preferably is benzyl

10 alcohol. A preferred cyclodextrin is a hydroxypropyl- β -cyclodextrin, which reduces QS-21 lysis of red blood cells *in vitro*.

The term "immune adjuvant," as used herein, refers to compounds which, when administered to an individual or tested *in vitro*, increase the

15 immune response to an antigen in the individual or test system to which said antigen is administered. Preferably, such individuals are humans, however, the invention is not intended to be so limiting. Any animal that may

20 experience the beneficial effects of the vaccines of the invention are within the scope of animals which may be treated according to the claimed invention. Some antigens are weakly immunogenic when administered alone or are toxic to the individual at concentrations which evoke immune responses in said

25 individual. An immune adjuvant may enhance the immune response of the individual to the antigen by making the antigen more strongly immunogenic. The adjuvant effect may also lower the dose of said antigen necessary to achieve an immune response in said individual.

30 The saponins of the present invention may be utilized to enhance the immune response to any antigen. Typical antigens suitable for the immune-response provoking compositions of the present invention include antigens

derived from any of the following: viruses, such as influenza, feline leukemia virus, feline immunodeficiency virus, HIV-1, HIV-2, rabies, measles, hepatitis B, or hoof and mouth disease, bacteria, such as anthrax, diphtheria, Lyme disease or tuberculosis; or protozoans, such as *Babesiosis bovis* or Plasmodium. The antigens may be proteins, peptides, polysaccharides, lipids, or nucleic acids encoding the protein or peptide. The proteins, peptides, lipids, or nucleic acids may be purified from a natural source, synthesized by means of solid phase synthesis, or may be obtained means of recombinant genetics.

Administration of the compounds useful in the method of the present invention may be by parenteral, intravenous, intramuscular, subcutaneous, intranasal, oral or any other suitable means. The dosage administered may be dependent upon the age, weight, species, kind of concurrent treatment, if any, route of administration, and nature of the antigen administered. In general, the saponin and antigen may be administered at a dosage of about 0.001 to about 1.0 mg/kg of saponin adjuvant or antigen per weight of the individual. The initial dose may be followed up with a booster dosage after a period of about four weeks to enhance the immunogenic response. Further booster dosages may also be administered.

The effective compound useful in the method of the present invention may be employed in such forms as capsules, liquid solutions, suspensions or elixirs for oral administration, or sterile liquid forms such as solutions or suspensions. The vaccine of the present invention may be administered parenterally, intranasally, or orally.

Another preferred embodiment is a method for reducing the *in vitro* lytic effect of an immune adjuvant composition comprising administering to an

individual an effective amount of QS-21 and an excipient. Preferably, the excipients may be nonionic surfactants, polyvinylpyrrolidone, human serum albumin, aluminum hydroxide, agents with anesthetic action, and various
5 unmodified and derivatized cyclodextrins. More preferably, the nonionic surfactants may include Polysorbate 20, Polysorbate 40, Polysorbate 60, and Polysorbate 80. The polyvinylpyrrolidone may preferably be Plasdone C15, a pharmaceutical grade of polyvinylpyrrolidone. The agent having anesthetic
10 action preferably is benzyl alcohol. A preferred cyclodextrin is Encapsin, a hydroxypropyl- β -cyclodextrin, which reduces QS-21 lysis of red blood cells *in vitro*.

Other preferred methods falling within the scope of the invention
15 include a method for maintaining the maximum adjuvant activity of QS-21 comprising administering to an individual an effective amount of QS-21 and an excipient and a method for improving the tolerance to saponin adjuvant associated pain in an individual to whom it is administered comprising
20 administering an effective amount of QS-21 and an excipient.

EXAMPLES

25 A variety of excipients were evaluated in combination with QS-21 as novel compositions. These included various nonionic surfactants (Triton X-100, Polysorbate 20, Polysorbate 40, Polysorbate 60, and Polysorbate 80), polyvinylpyrrolidone (Plasdone C15), human serum albumin, aluminum
30 hydroxide, agents with anesthetic action (benzyl alcohol), and various unmodified and derivatized cyclodextrins (hydroxypropyl- β -cyclodextrin, hydroxypropyl- γ -cyclodextrin, methyl- β -cyclodextrin). The final formulations

were assessed for their capacity to reduce the lytic effect of QS-21, to improve tolerance to QS-21 adjuvant associated pain in humans, to stabilize QS-21 in aqueous solution, and/or to maintain maximum adjuvant potency relative to a control formulation of QS-21 in PBS.

Example 1

Compositions that Reduce the Lytic Effect of QS-21

A simple *in vitro* assay was used to screen excipients for reducing the lytic effect of QS-21. The lytic effect of QS-21 can be determined in an assay of hemolysis of sheep erythrocytes. Briefly, various two fold serial dilutions of QS-21 in a given excipient are prepared in a round bottom microtiter plate (100 μ l/well). All plates contain control wells containing excipient, but no QS-21. The concentration of QS-21 ranges from 1.56 to 200 μ g/ml. A total volume of 25 μ l of sheep erythrocytes (washed with PBS) is added to each well, mixed with the QS-21/excipient solution, and incubated at ambient temperature for 30 minutes. After the end of the incubation, the round bottom plate is centrifuged at 2000 rpm for 5 minutes to sediment any unlysed cells. A total volume of 75 μ l of supernatant (containing released hemoglobin) is transferred to the equivalent well of a flat-bottom 96 well plate. The flat-bottom plate is centrifuged at 2000 rpm for 5 minutes to break any air bubbles. The absorbance at 570 nm is read in a microtiter plate reader. Absorbance at 570 nm is plotted on the y-axis against QS-21 concentration plotted on the x-axis. The absorbance of hemoglobin in the supernatant of a well where no intact cell pellet was observed is defined as maximum hemolysis. The hemolytic index of QS-21 is defined as the concentration of QS-21 that yields

an absorbance equivalent to 50% of the maximum absorbance. An excipient that reduces the lytic effect of QS-21 is expected to increase the hemolytic index.

5 Table 1 lists the hemolytic indices of QS-21 in various excipients. All excipients were tested in the absence of QS-21. In the absence of QS-21, no hemolysis was noted, indicating that the excipient formulations were isotonic. Excipients that were shown to be effective in minimizing the lytic effect
10 (increase hemolytic index) of QS-21 were hydroxypropyl- β -cyclodextrin, aluminum hydroxide, and Polysorbate 80 in saline.

15

20

25

30

Table 1:

| | Excipient | Hemolytic Index (µg/ml) |
|----|---|-------------------------|
| | PBS | 5 |
| 5 | α-cyclodextrin (2 mg/ml) | 1.5 |
| | β-cyclodextrin (2 mg/ml) | 10 |
| | methyl-β-cyclodextrin (2 mg/ml) | 36 |
| | hydroxypropyl-γ-cyclodextrin (2 mg/ml) | 5 |
| | hydroxypropyl-β-cyclodextrin (1 mg/ml) | 9 |
| 10 | hydroxypropyl-β-cyclodextrin (2 mg/ml) | 11 |
| | hydroxypropyl-β-cyclodextrin (4 mg/ml) | 18 |
| | hydroxypropyl-β-cyclodextrin (8 mg/ml) | 32 |
| | hydroxypropyl-β-cyclodextrin (16 mg/ml) | 51 |
| 15 | hydroxypropyl-β-cyclodextrin (32 mg/ml) | 93 |
| | human serum albumin (40 mg/ml) | 9 |
| | QS-7 (250 µg/ml) | 30 |
| | aluminum hydroxide (2 mg/ml) in PBS | 5 |
| | aluminum hydroxide (2 mg/ml) in saline | 13 |
| 20 | Monophosphoryl lipid A (25 µg/ml) | 4.9 |
| | Monophosphoryl lipid A (50 µg/ml) | 7.7 |
| | Monophosphoryl lipid A (100 µg/ml) | 6.5 |
| | Triton X-100 (50 µg/ml) | 1 |
| | Triton X-100 (100 µg/ml) | 1 |
| 25 | Polysorbate 80 (2 mg/ml) | 9 |
| | Polysorbate 80 (4 mg/ml) | 18 |
| | Polysorbate 80 (10 mg/ml) | 38 |

30

Example 2

Compositions that Reduce the Lytic Effects of Other Saponins

Other saponin adjuvants are also known to be hemolytic, although to
5 different extent than QS-21. These saponins include substantially pure QS-7,
QS-17, and QS-18. In addition, heterogeneous adjuvant saponins such as
Quil A are hemolytic. An example of the effect of Polysorbate 80 and
hydroxypropyl- β -cyclodextrin on the hemolytic indices of the substantially
10 pure QS-7 and heterogeneous Quil A is shown in Table 2. Hydroxypropyl- β -
cyclodextrin was shown to be effective in reducing the lytic effect (increasing
the hemolytic index) of QS-7. Polysorbate 80 and hydroxypropyl- β -
cyclodextrin were shown to be effective in minimizing the lytic effect
15 (increasing the hemolytic index) of Quil A.

Table 2:

| Saponin | Excipient | Hemolytic Index ($\mu\text{g/ml}$) |
|-----------|---|--------------------------------------|
| 20 QS-7 | PBS | 650 |
| QS-7 | Polysorbate 80 (8 mg/ml) | 60 |
| QS-7 | Hydroxypropyl- β -cyclodextrin (32 mg/ml) | >1000 |
| Quil A | PBS | 18 |
| Quil A | Polysorbate 80 (8 mg/ml) | 43 |
| 25 Quil A | Hydroxypropyl- β -cyclodextrin (32 mg/ml) | 200 |

Example 3

30

Compositions that Stabilize QS-21

QS-21 is an acylated bidesmodic triterpene saponin. It has a fatty acid
ester linked to the hydroxyl residues of fucose. In aqueous solution, this fatty

acid ester migrates between two adjacent vicinal hydroxyl groups (fucose 3, 4) to form two equilibrium isomers (Jacobsen, N.E., Fairbrother, W.J., et al., 1996, Carbohydrate Research 280:1-14). The predominant isomer is acylated at fucose 4 and the minor isomer is acylated at fucose 3. This ester bond is the most labile bond in QS-21 and will hydrolyze under alkaline conditions to form a deacylated saponin and a fatty acid-arabinose domain. The deacylated saponin and the fatty acid domain are both inactive as immunological adjuvants (Kensil, C.R., et al., 1996, In: Saponins Used in Traditional and Modern Medicine, Waller and Yamaski, Eds., Plenum Press, NY, 165-172). Various conditions affect the stability of this ester bond (Cleland, J.L., et al., 1996, J. Pharmaceutical Sciences 85:22-28). Furthermore, the monomer form of QS-21 is more susceptible to hydrolysis than the micellar form.

Examples of the shelf life of QS-21 are shown in Table 3. The aqueous shelf life for a 50 µg/ml QS-21 solution at pH 7.0 at 4°C was shown to be only 94 days or approximately 3 months. This is representative of a typical clinical vaccine formulation containing QS-21 adjuvant (which consists of QS-21 at a concentration of 50-200 µg/ml in a physiological pH buffer (pH 7.0-7.5)). Hence, in simple buffer and salt solutions at low concentration, the QS-21 product does not maintain a desirable stability profile. Some improvement in stability, however, can be achieved by an increased concentration of the QS-21 product. For instance, the shelf life of a 500 µg/ml QS-21 solution at pH 7.0 at 4°C was shown to be 717 days, or 23.9 months. But a concentrated QS-21 solution is not necessarily a practical method of administering a low dose of adjuvant. For example, administration of 25 µg from a 500 µg/ml solution would require the syringe withdrawal of 0.05 ml of dose. Additionally, some

improved stability can be achieved by the use of a lower pH, i.e., at pH 6.0.

However, a pH substantially lower than the physiological pH range may not be tolerated well or be compatible with the antigen.

5 Table 3:

| | QS-21 Concentration | pH | t_{90} (days) |
|----|---------------------|--------|-----------------|
| | 50 µg/ml | pH 7.0 | 94 |
| | 50 µg/ml | pH 6.0 | 679 |
| 10 | 500 µg/ml | pH 7.0 | 717 |

Another way to evaluate the stability of QS-21 in aqueous solution was to assay the solution by HPLC in an accelerated stability assay at 37°C.

15 Although this is not the temperature used for storage of vaccines (4°C), it was expected that this assay at 37°C would show the relative stabilizing power of a given excipient. For example, an excipient that extended the t_{90} value by two fold at 37°C would also be expected to extend the t_{90} value by two fold at 4°C.

20 Specifically, QS-21 (100 µg/ml) was prepared in various excipients in PBS at pH 7.0. The solutions were incubated at 37°C for 7 days. At the end of 7 days, the solutions were assayed by reversed phase-HPLC to determine the extent of degradation. The data was plotted as log (fraction QS-21 $t=7$ /QS-21 $t=0$ days) against time on the x-axis. The time to 10% degradation (t_{90}) was
25 extrapolated from this plot.

Table 4 shows the t_{90} values of QS-21 in various excipients. Stabilization
30 of QS-21 is shown by an increase in t_{90} . Excipients that stabilized QS-21 by at least two fold are Polysorbate 20, Polysorbate 80, native *Quillaja* saponin QS-7, and the deacylsaponin resulting from alkaline hydrolysis of QS-21 (DS-1).

Table 4:

| | Excipient | t_{90} (days) at 37°C |
|----|---|-------------------------|
| | PBS (pH 7.0) | 1.2 |
| 5 | Polysorbate 20 (720 µg/ml) | 2.9 |
| | Polysorbate 80 (250 µg/ml) | 3.2 |
| | Polysorbate 80 (500 µg/ml) | 4.3 |
| | Polysorbate 80 (1.0 mg/ml) | 5.2 |
| | Polysorbate 80 (2.0 mg/ml) | 7.2 |
| 10 | Phenol (2.5 mg/ml) | 2.3 |
| | Pluronic F68 (1.0 mg/ml) | 1.4 |
| | QS-7 (100 µg/ml) | 1.8 |
| | QS-7 (250 µg/ml) | 2.6 |
| 15 | QS-7 (500 µg/ml) | 9.0 |
| | QS-7 (1.0 mg/ml) | 16.0 |
| | DS-1 (100 µg/ml) | 2.2 |
| | DS-1 (250 µg/ml) | 3.3 |
| | DS-1 (500 µg/ml) | 7.2 |
| 20 | DS-1 (1.0 mg/ml) | 6.2 |
| | Monocaproyl-rac-glycerol (1.0 mg/ml) | 1.7 |
| | α -cyclodextrin (5 mg/ml) | 0.8 |
| | β -cyclodextrin (5 mg/ml) | 0.7 |
| 25 | Methyl- β -cyclodextrin (5 mg/ml) | 1.5 |
| | hydroxypropyl- γ -cyclodextrin (5 mg/ml) | 1.0 |
| | hydroxypropyl- β -cyclodextrin (5 mg/ml) | 1.0 |

In addition, 0.9% benzyl alcohol, and Plasdane C15 were evaluated for its ability to stabilize QS-21 (Table 5). All QS-21 concentrations and incubation conditions were equivalent in this experiment except that the QS-21 formulation was prepared in Dulbecco's PBS (without calcium or magnesium)

at pH 7.5. As expected, the higher pH resulted in a faster degradation of QS-21 in PBS. However, Plasdane C15 stabilized QS-21.

5 Table 5:

| | Excipient | t_{90} (days) at 37°C, pH 7.5 |
|----|---|---------------------------------|
| | Dulbecco's PBS | 0.6 |
| | 0.9% benzyl alcohol in Dulbecco's PBS | 0.7 |
| 10 | Plasdane C15 in Dulbecco's PBS (25 mg/ml) | 1.6 |
| | Plasdane C15 in Dulbecco's PBS (50 mg/ml) | 7.7 |

Example 4

15

Adjuvant Potency of Compositions

Figures 1A and 1B show the effect of Polysorbate 40, Polysorbate 60, Polysorbate 80, and methyl- β -cyclodextrin on the immune response of Balb/c mice to OVA plus various doses of QS-21. Female mice (10/group, 8-10 weeks of age at the first immunization) were immunized subcutaneously with 5 μ g of OVA and the indicated dose of QS-21 in either PBS alone or in 2 mg/ml excipient in PBS. A booster immunization was given by the same route at week 2. Sera was collected at week 4 for EIA analysis of the anti-OVA response. Mice were analyzed for OVA-specific IgG2a by a standard EIA analysis (Kensil, C.R., et al., 1993, Vaccine Research 2:273-281). QS-21 was active in all excipients within two fold of the threshold value determined in PBS. The same maximum level of antibody response was reached at the optimum adjuvant dose (typically 10 μ g and above).

Figure 2 shows the effect of excipients on antibody response to a T-independent polysaccharide antigen. Balb/c mice were immunized subcutaneously with a commercial 23-valent *S. pneumonia* polysaccharide vaccine (Pnu-Imune, 0.5 µg/serotype) and different doses of QS-21 in PBS, in 4 mg/ml Polysorbate 80 in PBS, or in 16 mg/ml hydroxypropyl-β-cyclodextrin in PBS. Anti-Type 14 IgG was determined by EIA on sera collected at day 7 after a single immunization. Neither Polysorbate 80 or hydroxypropyl-β-cyclodextrin in the formulation reduced the potency of the vaccine for stimulating an IgG3 response specific for Type 14 polysaccharide serotype.

Example 5

Clinical Studies of Compositions-Trial 1

Various QS-21 compositions were administered to patients in order to test for the compositions' pain tolerance. Fifteen volunteers were recruited to receive four intramuscular injections, with each injection given at one week intervals. The study was carried out as a randomized, double-blind study. Three of the formulations contained 50 µg QS-21 in either Dulbecco's PBS (without calcium or magnesium), in 4 mg/ml Polysorbate 80 in PBS, or in 1 mg/ml aluminum hydroxide in saline. The fourth formulation was a PBS control without QS-21. Volunteers were asked to rate the immediate pain in the first five minutes after injection on a 0 to 10 scale (0=no pain, 1-3=mild, 4-7=moderate, 8-10=severe). The results are shown in Figure 3. The cumulative scores represented in Figure 3 of the patients' tolerance to pain is represented in Figure 4 as individual scores. The QS-21 formulation containing 4 mg/ml Polysorbate 80 resulted in an improved pain tolerance compared to QS-21 in

PBS. The highest score for this particular formulation was rated as a 5.

Example 6

5 Clinical Studies of Compositions-Trial 2

Various other QS-21 compositions were administered to patients in order to test for the compositions' pain tolerance. Fifteen volunteers were recruited to receive four intramuscular injections, with each injection given at
10 one week intervals. The study was carried out as a randomized, double-blind study. The excipients evaluated were benzyl alcohol, hydroxypropyl-beta-cyclodextrin, and a higher dose of Polysorbate 80, which had been shown to be
15 more effective than 4 mg/ml Polysorbate 80 at reducing QS-21 lysis of red blood cells *in vitro*. The five formulations tested were (1) 1 mg/ml aluminum hydroxide, which served as the placebo control; (2) 50 µg QS-21 in 0.72% benzyl alcohol in saline; (3) 50 µg QS-21 in 30 mg/ml hydroxypropyl-β-
20 cyclodextrin; (Encapsin, Janssen Biotech N.V., Olen, Belgium) (4) 50 µg QS-21 in 8 mg/ml Polysorbate 80; and (5) 50 µg QS-21 in PBS (Dulbecco's PBS without calcium or magnesium), which served as a positive control
25 formulation. Volunteers were asked to rate the immediate pain in the first five minutes after injection on a 0 to 10 scale (0=no pain, 1-3=mild, 4-7=moderate, 8-10=severe). The results are shown in Figure 5. The cumulative scores represented in Figure 5 of the patients' tolerance to pain is represented in
Figure 6 as individual scores. All excipients were shown to reduce the mean
30 and median pain scores associated with QS-21 in PBS. The highest single score for the QS-21/Encapsin formulation was rated as a 5, which compared more

favorably with the QS-21/Polysorbate 80 formulation that was rated with a single 6 and two 5's.

5 The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth below.

10

15

20

25

30

We claim:

1. A composition comprising an antigen, a saponin adjuvant, and an excipient, wherein the composition reduces the *in vitro* lytic effect of the saponin adjuvant.
5
2. The composition according to claim 1, wherein the saponin adjuvant is a substantially pure saponin adjuvant.
3. The composition according to claim 2, wherein the substantially pure saponin adjuvant is QS-7 or QS-21.
10
4. The composition according to claim 1, wherein the saponin adjuvant is a heterogenous saponin adjuvant.
5. The composition according to claim 4, wherein the heterogeneous saponin adjuvant is Quil A.
15
6. The composition according to claim 1, wherein the antigen is a peptide, a protein, a polysaccharide, a lipid, or a nucleic acid encoding the peptide or protein.
20
7. The composition according to claim 1, wherein the excipient is a nonionic surfactant.
8. The composition according to claim 7, wherein the nonionic surfactant is a Polysorbate.
25
9. The composition according to claim 8, wherein the Polysorbate is Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.
10. The composition according to claim 1, wherein the excipient is a cyclodextrin.
30
11. The composition according to claim 10, wherein the cyclodextrin is

β -cyclodextrin.

12. The composition according to claim 11, wherein the β -cyclodextrin is hydroxypropyl- β -cyclodextrin.

5 13. The composition according to claim 1, wherein the composition further maintains the maximum adjuvant activity of QS-21.

14. The composition according to claim 13, wherein the saponin adjuvant is a substantially pure saponin adjuvant.

10 15. The composition according to claim 14, wherein the substantially pure saponin adjuvant is QS-7 or QS-21.

16. The composition according to claim 13, wherein the saponin adjuvant is a heterogenous saponin adjuvant.

15 17. The composition according to claim 16, wherein the heterogeneous saponin adjuvant is Quil A.

18. The composition according to claim 13, wherein the antigen is a peptide, a protein, a polysaccharide, a lipid, or a nucleic acid encoding the peptide or protein.

19. The composition according to claim 13, wherein the excipient is a nonionic surfactant.

25 20. The composition according to claim 19, wherein the nonionic surfactant is a Polysorbate.

21. The composition according to claim 20, wherein the Polysorbate is Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

30 22. The composition according to claim 13, wherein the excipient is a cyclodextrin.

23. The composition according to claim 22, wherein the cyclodextrin is β -cyclodextrin.

24. The composition according to claim 23, wherein the cyclodextrin is
5 hydroxypropyl- β -cyclodextrin.

25. The composition according to claim 1, wherein the composition further has an increased stability.

26. The composition according to claim 25, wherein the saponin
10 adjuvant is a substantially pure saponin adjuvant.

27. The composition according to claim 26, wherein the substantially pure saponin adjuvant is QS-7 or QS-21.

28. The composition according to claim 25, wherein the saponin
15 adjuvant is a heterogenous saponin adjuvant.

29. The composition according to claim 28, wherein the heterogeneous saponin adjuvant is Quil A.

20 30. The composition according to claim 25, wherein the antigen is a peptide, a protein, a polysaccharide, a lipid, or a nucleic acid encoding the peptide or protein.

31. The composition according to claim 25, wherein the excipient is a
25 nonionic surfactant.

32. The composition according to claim 31, wherein the nonionic surfactant is a Polysorbate.

33. The composition according to claim 26, wherein the Polysorbate is
30 Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

34. The composition according to claim 1, wherein the composition

further improves the tolerance to saponin adjuvant associated pain in an individual to whom it is administered.

35. The composition according to claim 34, wherein the saponin
5 adjuvant is a substantially pure saponin.

36. The composition according to claim 35, wherein the substantially pure saponin adjuvant is QS-7 or QS-21.

37. The composition according to claim 34, wherein the saponin
10 adjuvant is a heterogenous saponin adjuvant.

38. The composition according to claim 37, wherein the heterogeneous saponin adjuvant is Quil A.

39. The composition according to claim 34, wherein the antigen is a
15 peptide, a protein, a polysaccharide, a lipid or a nucleic acid encoding the peptide or protein.

40. The composition according to claim 34, wherein the excipient is a
20 nonionic surfactant.

41. The composition according to claim 40, wherein the nonionic surfactant is a Polysorbate.

42. The composition according to claim 41, wherein the Polysorbate is
25 Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

43. The composition according to claim 34, wherein the excipient is a cyclodextrin.

44. The composition according to claim 43, wherein the cyclodextrin is
30 β -cyclodextrin.

45. The composition according to claim 44, wherein the cyclodextrin is

hydroxypropyl- β -cyclodextrin.

5

10


15

20

25

30

1/7



QS-21 DOSE (ug)

FIG. 1A

RECTIFIED SHEET (RULE 91)
ISA/EP

2/7




FIG. 1B

RECTIFIED SHEET (RULE 91)
ISA/EP

3/7




FIG. 2

RECTIFIED SHEET (RULE 91)
ISA/EP

4/7




FIG. 3

RECTIFIED SHEET (RULE 91)
ISA/EP




FIG. 4

RECTIFIED SHEET (RULE 91)
ISA/EP




FIG. 5

7/7




FIG. 6

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 98/17940

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K39/39 //(A61K39/39, 47:40, 47:34)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-------------------------|
| X | US 5 650 398 A (SOLTYSIK SEAN ET AL) 22 July 1997 see column 1, line 12-17 see column 2, line 36-48 see column 6, line 10-24 see column 21, line 14-32 see column 22, line 3-36 see column 24, line 19-42 | 1-9, 13-21, 25-42 |
| X | PATENT ABSTRACTS OF JAPAN vol. 095, no. 003, 28 April 1995 & JP 06 343419 A (DR MAINTSU:KK), 20 December 1994 see abstract ----- -/- | 1,2,4,6, 10 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

20 January 1999

Date of mailing of the international search report

01/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Covone, M

INTERNATIONAL SEARCH REPORT

Int'l. Application No.
PCT/US 98/17940

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|--|
| X | <p>WO 91 04052 A (PEPTIDE TECHNOLOGY LTD) 4 April 1991</p> <p>see page 3, line 19 - page 4, line 2 see page 4, line 28 - page 5, line 17 see claims 1-6</p> | <p>1,2,4-6, 25,26, 28-30, 34,35, 37-39</p> |
| X | <p>EP 0 187 286 A (BEHRINGWERKE AG) 16 July 1986</p> <p>see page 1, line 14 - page 2, line 4 see example 7 see claims 1,5,6</p> | <p>1-9, 13-21, 25-42</p> |
| X | <p>US 4 806 350 A (GERBER JAY D) 21 February 1989</p> <p>see column 1, line 64 - column 2, line 3 see column 3, line 47-59</p> | <p>1-9, 13-21, 25-42</p> |
| X | <p>GB 1 083 815 A (RALPH ARTHUR NEAL) 20 September 1967</p> <p>see page 1, left-hand column, line 43 - right-hand column, line 52 see page 2, right-hand column, line 90-98</p> | <p>1,2,4-6</p> |
| A | <p>WO 96 20008 A (SOLVAY ;HILGERS LUUK (NL)) 4 July 1996</p> <p>see page 2, line 31-33 see page 7, line 5-33 see claims 1,2,4</p> | <p>10-12, 22-24, 43-45</p> |
| P,X | <p>WO 98 15287 A (SMITHKLINE BEECHAM BIOLOG ;FRIEDE MARTIN (BE); GARCON NATHALIE (BE)) 16 April 1998</p> <p>see page 1, line 12-15 see page 2, line 3-7 see page 3, line 21-23 see example 5 see claims 1,2,15</p> | <p>1-6, 13-18, 25-30, 34-39</p> |
| E | <p>EP 0 884 056 A (SMITHKLINE BEECHAM BIOLOG) 16 December 1998</p> <p>see page 2, line 6-14 see page 4, line 24 - page 5, line 40</p> | <p>1-6, 13-18, 25-30, 34-39</p> |

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 98/17940

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|--|
| US 5650398 A | 22-07-1997 | US 5443829 A US 5273965 A AU 6039396 A CA 2223063 A EP 0841932 A WO 9638161 A AU 687005 B AU 4664993 A CA 2139437 A EP 0658111 A FI 946173 A HU 73814 A JP 7509440 T MX 9303977 A NO 945071 A WO 9401118 A | 22-08-1995 28-12-1993 18-12-1996 05-12-1996 20-05-1998 05-12-1996 19-02-1998 31-01-1994 20-01-1994 21-06-1995 15-02-1995 30-09-1996 19-10-1995 29-04-1994 01-03-1995 20-01-1995 |
| WO 9104052 A | 04-04-1991 | AU 640414 B AU 6421090 A CA 2066653 A EP 0491833 A | 26-08-1993 18-04-1991 23-03-1991 01-07-1992 |
| EP 0187286 A | 16-07-1986 | DE 3446515 A DK 593985 A FI 855057 A GR 853058 A PT 81713 B | 26-06-1986 21-06-1986 21-06-1986 15-04-1986 10-08-1987 |
| US 4806350 A | 21-02-1989 | AU 609667 B AU 7176087 A CA 1282003 A DE 3787663 D DE 3787663 T DK 190387 A EP 0242205 A ES 2059369 T IE 61233 B JP 2515321 B JP 62255436 A PT 84692 B | 02-05-1991 22-10-1987 26-03-1991 11-11-1993 17-02-1994 19-10-1987 21-10-1987 16-11-1994 19-10-1994 10-07-1996 07-11-1987 30-11-1989 |
| GB 1083815 A | | NONE | |
| WO 9620008 A | 04-07-1996 | BE 1008978 A AU 4324896 A AU 4324996 A WO 9620222 A BR 9510223 A BR 9510263 A CA 2208790 A CA 2208849 A CN 1171052 A CN 1175264 A EP 0814836 A EP 0800539 A JP 10511997 T | 01-10-1996 19-07-1996 19-07-1996 04-07-1996 30-12-1997 04-11-1997 04-07-1996 04-07-1996 21-01-1998 04-03-1998 07-01-1998 15-10-1997 17-11-1998 |
| WO 9815287 A | 16-04-1998 | AU 4781297 A | 05-05-1998 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/17940

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP 0884056 A | 16-12-1998 | AU 693022 B | 18-06-1998 |
| | | AU 5334596 A | 18-11-1996 |
| | | AU 699213 B | 26-11-1998 |
| | | AU 6987398 A | 23-07-1998 |
| | | CA 2217178 A | 31-10-1996 |
| | | CN 1182370 A | 20-05-1998 |
| | | CZ 9703379 A | 18-03-1998 |
| | | WO 9633739 A | 31-10-1996 |
| | | EP 0822831 A | 11-02-1998 |
| | | HU 9801560 A | 28-10-1998 |
| | | NO 974859 A | 21-10-1997 |
| | | PL 322968 A | 02-03-1998 |
| | | SK 144297 A | 06-05-1998 |